Date: 2012-02-27
Type of information: Licensing agreement
Compound: TrueSpike™ technology
Company: EMD Millipore, Life Science division of Merck KGaA - Germany (USA) Charles River Laboratories (USA)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: TrueSpike™ technology enables removal of cell debris, DNA, and non-viral proteins from virus preparations used to validate biomanufacturing process virus clearance. Use of TrueSpike™ technology reduces the protein content of virus preparations used for validation studies up to 600 fold, as demonstrated with TrueSpike MVM (minute mouse virus).
Disease:
Details: EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, has announced that it will be partnering with Charles River Laboratories International, Inc., to exclusively license EMD Millipore’s TrueSpike™ technology. EMD Millipore and Charles River will collaborate to integrate the TrueSpike™ technology into viral clearance services provided by Charles River, which is designed to result in a more predictable and consistent study outcome for clients, and ultimately helping to improve drug product safety. The combined expertise of these two industry leaders will result in higher purity virus preparations to help ensure validation success and regulatory compliance for biopharmaceutical manufacturers.
Financial terms:
Latest news:
